Sep. 25 at 11:35 PM
$OABI
OABI Business model is different than most biotechs. That’s why it’s having a hard time gaining traction.
It depends on its customers success more than developing its own drugs through trials. Wall Street has a hard time valuing a biotech license company. Especially an early stage company like AOBI.
Right now investors are just looking at the cash burn rate.
They have big name customers but with confidential agreements set up we dont see many press releases about specific deals.
You have to wait for each quarter CC to get any color of progress.
All that being said makes it challenging to get any significant volume for a penny stock
However their science is unique and eventually customer growth will show up.
Reminds me of another LGND spinoff VKTX when you couldn’t give it away at1.25
This low price on OABI won’t last forever
